Skip to content
Back to news

World Parkinson’s Day: Taking action for patients and blazing a trail for innovation

Parkinson’s disease is the result of the slow and progressive degeneration of neurons. These include dopaminergic neurons found in the part of the brain responsible for producing dopamine, a neurotransmitter involved in the control of movement. .

60 years

is the average age at diagnosis3.

The disease is complex, given that other neurotransmitters may also be affected by neuronal degeneration. Consequently, other symptoms may arise as the disease progresses, including mood disorders, sleep disturbances, cognitive deficits, constipation, urinary incontinence, problems with swallowing, smell, etc. In advanced stages, Parkinson’s leads to progressive and total loss of autonomy for patients. 

To find out more, read our insight on Parkinson’s, the second most common neurodegenerative disease after Alzheimer’s.

Servier has collaborating with the Parkinson’s Europe organization for many years, by actively supporting their World Parkinson’s Day awareness campaign. This year, the campaign focuses on the benefits of physical activity and exercise for people with Parkinson’s disease. 

Servier and the Saclay Research & Development Patient Board have teamed up to produce podcasts with and for patients. In this episode, we meet Estelle, who suffers from endometriosis, and Veerle, who has been diagnosed with Parkinson’s disease. Estelle and Veerle are two women with two stories and two inspiring and engaging journeys! ! 

Listen to the podcast on your favorite platform here.

To address a major and growing medical need, and as part of our Servier 2030 strategy, we aim to be an industry innovator in the field of neuroscience. To achieve this, we are investing heavily in R&D, taking a patient-centered approach, and focusing on the development of targeted therapies.

Did you know ?

Neurodegenerative diseases are chronic disorders that progress toward a total loss of autonomy.

In January 2024, we announced a new collaboration with Aitia on Parkinson’s disease. Aitia’s Gemini Digital Twin technology will be used to identify sub-populations of patients who may respond favorably to the LRRK2 treatment currently being developed by Servier. 

[1] Source : N. Maserejian, L. Vinikoor-Imler, A. Dilley (Cambridge, MA, USA), Estimation of the 2020 Global Population of Parkinson’s Disease (PD) Meeting: MDS Virtual Congress 2020
[2] Source : What next in Parkinson’s disease? Lancet. 2024 Jan 20;403(10423):219. doi: 10.1016/S0140-6736(24)00094-1.
[3] Source :